Baxter introduces subcutaneous immunoglobulin treatment Hyqvia in US

Baxter International and Halozyme Therapeutics have announced the launch of Hyqvia in the US, a subcutaneous immunoglobulin treatment for adult patients with primary immunodeficiency (PI).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news